Location Directory

Clinical trials in Indianapolis, Indiana

This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3636

Shown on this page

Local exact-city summaries

3636

Based on exact city/state matches in the local index.

Local exact-city recruiting

656

Live official results below use the broader ClinicalTrials.gov location search.

The trial list below is retrieved from the live ClinicalTrials.gov search API for Indianapolis, Indiana. Results on this page are currently sorted by Recently updated. Use the filter controls below to narrow by condition, treatment, sponsor, recruitment status, phase, study type, sex, or age.

Showing 1–12 of 3,636 matching trials in Indianapolis, IN.

Indexed local directory records.

The summary panels and records below use exact city/state matches from the local directory for Indianapolis, IN. Use the filters or full search link when you want broader live ClinicalTrials.gov location matching.

Top conditions in local exact-city summaries

Breast Cancer 89 HIV Infections 62 Leukemia 53 Multiple Myeloma 52 Diabetes Mellitus, Type 2 46 Atopic Dermatitis 41

Top sponsors in local exact-city summaries

Indiana University 321 National Cancer Institute (NCI) 249 Children's Oncology Group 200 Eli Lilly and Company 123 Pfizer 92 Novartis Pharmaceuticals 69

Top therapies in local exact-city summaries

Carboplatin 89 Cyclophosphamide 86 Paclitaxel 77 Pembrolizumab 67 Dexamethasone 61 radiation therapy 60

Indexed official records

Open in full search

Conditions: Cognitive Behavior Therapy, Depression in Adults, HIV, Insulin Resistance
Interventions: Active Control (AC), Internet cognitive behavioral therapy (iCBT-D); Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Epilepsy, Epilepsy (Treatment Refractory)
Interventions: Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system); Device
Lead sponsor: Epiminder America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Phoenix, Arizona • Irvine, California • Palo Alto, California + 13 more

Conditions: Endometrial Cancer, Malignant Solid Tumour
Interventions: Doxorubicin, Paclitaxel, Puxitatug Samrotecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 66
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 57 more

Conditions: Crohn's Disease, Obesity or Overweight
Interventions: Mirikizumab, Placebo, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 35
States / cities: Dothan, Alabama • Anaheim, California • Beverly Hills, California + 29 more

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Cyclophosphamide, Methotrexate (MTX), Mycophenolate mofetil (MMF), Ruxolitinib (Rux), Tacrolimus (Tac); Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 30
States / cities: Palo Alto, California • San Francisco, California • Miami, Florida + 23 more

Conditions: Colorectal Cancer
Interventions: Fruquintinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more

Conditions: Large B-cell Lymphoma
Interventions: Cyclophosphamide, Fludarabine, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, cemacabtagene ansegedleucel; Drug · Device · Genetic
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 58
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 47 more

Conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Durvalumab, Patient Observation, Questionnaire Administration; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2039
U.S. locations: 230
States / cities: Jonesboro, Arkansas • Beverly Hills, California • Loma Linda, California + 186 more

Conditions: Gram-negative Bacterial Infection
Interventions: Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Up to 39 Weeks
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Orange, California • Aurora, Colorado • Indianapolis, Indiana + 5 more

Conditions: Diabetes Mellitus, Type 2, Metabolic Syndrome, PreDiabetes
Interventions: The Cleerly CAD Staging System; Device
Lead sponsor: Cleerly, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 7,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 124
States / cities: Chandler, Arizona • Scottsdale, Arizona • Sun City, Arizona + 99 more

Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Questionnaire Administration; Drug · Procedure · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 70 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 318
States / cities: Fayetteville, Arkansas • Fort Smith, Arkansas • Rogers, Arkansas + 251 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions: Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 534
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 411 more

Clinical trials in Indianapolis, Indiana

Filter and sort this location

Top conditions in local exact-city summaries

Top sponsors in local exact-city summaries

Top therapies in local exact-city summaries

Indexed official records

The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV

Diagnosing Epilepsy To EffeCT Change

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer